AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
AstraZeneca is betting roughly $1.35 billion on Korean biotech Alteogen to help develop under-the-skin versions of multiple ...
Anglo-Swedish pharma major AstraZeneca and Korean biotech Alteogen have entered into an exclusive license agreement for ...
Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...
To leverage Alteogen's ALT-B4 Hybrozyme platform technology for large volume subcutaneous administration of drugs.
HanAll Biopharma Co., Ltd. (KRX: 009420.KS), a global biopharmaceutical company committed to discovering and developing ...
Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...
Viking Therapeutics VKTX signed a broad multi-year manufacturing agreement with CordenPharma, a contract development and ...
Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
EsoBiotec develops therapies that engineer immune cells within the body, eliminating the need for patients to go through lymphodepletion and reinfusion.